Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway.
Oncol Rep
; 46(2)2021 Aug.
Article
em En
| MEDLINE
| ID: mdl-34184074
ABSTRACT
Lung cancer is the most common malignant tumor type and it is associated with poor prognosis. The identification of potential biomarkers is of great significance for the early diagnosis and treatment of lung cancer. Nonsmall cell lung cancer (NSCLC) is the most common pathological type of lung cancer. The present study aimed to investigate the mechanism via which thyroid hormone receptorinteracting protein 13 (TRIP13) participates in the malignant progression of NSCLC. Immunohistochemistry, reverse transcriptionquantitative PCR and western blotting were used to assess the expression level of TRIP13. According to The Cancer Genome Atlas database, TRIP13 was upregulated in NSCLC tissues compared with adjacent normal tissues. Moreover, TRIP13 knockdown increased apoptosis, induced cell cycle arrest in the S phase and inhibited the proliferation, invasion and migration of H1299 cells in vitro. Furthermore, TRIP13 upregulation was closely associated with tumor metastasis via epithelialmesenchymal transformation. In conclusion, TRIP13 could promote the malignant progression of lung cancer, and TRIP13 may be a potential biomarker for the early diagnosis and treatment of NSCLC.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Regulação para Cima
/
Carcinoma Pulmonar de Células não Pequenas
/
Proteínas de Ciclo Celular
/
ATPases Associadas a Diversas Atividades Celulares
/
Neoplasias Pulmonares
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article